Abstract
Sigma receptors are expressed in a wide variety of tumor cell lines, and are expressed in proliferating cells. A radioligand for the visualization of sigma receptors could be useful for selective detection of primary tumors and their metastases, and for non-invasive assessment of tumor proliferative status. To this end we evaluated two sigma receptor ligands, [11C]SA5845 and [11C]SA4503. In an in vitro study, AH109A hepatoma showed moderate densities of sigma1 and sigma2 receptors, and VX-2 carcinoma showed a high density of sigma2 receptors: Bmax (fmol/mg protein) for sigma1 vs. sigma2, 1,700 vs. 1,200 for AH109A hepatoma and 800 vs. 10,000 for VX-2 carcinoma. In a cell growth assay in vitro, neither SA5845 nor SA4503 (<10 μM) showed any inhibitory effect on proliferation of the AH109A hepatoma cells. In rats, the uptake of [11C]SA5845 and [11C]SA4503 in AH109A tissues was accumulated over the first 60 minutes; however, the uptake of both tracers increased by co-injection with haloperidol as a sigma receptor ligand. On the other hand, in the PET studies of rabbits, the uptake of [11C]SA5845 in the VX-2 carcinoma was relatively higher than that of [11C]SA4503, because of a much higher density of sigma2 receptors compared to sigma1 receptors in the VX-2 tissue, and the uptake of both tracers in the VX-2 tissue was decreased by carrier-loading and pre-treatment with haloperidol ([11C]SA5845, 53% and 26%, respectively; [11C]SA4503, 41% and 22%, respectively at 30 minutes after injection). Therefore, [11C]SA5845 and [11C]SA4503 may be potential ligands for PET imaging of sigma receptor-rich tumors.
Similar content being viewed by others
Reference
Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function.Pharmacol Rev 1990; 42:355–402.
Su TP, London ED, Jaffe JH. Steroid binding at σreceptors suggests a link between endocrine, nervous, immune systems.Science 1988; 240:219–221.
Wolfe SA Jr, Culp SG, De Souza EB. σ-receptors in endocrine organs: identification, characterization, and autoradiogaphic localization on rat pituitary, adrenal, testis and ovary.Endocrinology 1989; 124:1160–1172.
Hellewell SB, Bruce A, Feinstein G, Orringer J,. Williams W, Bowen WD. Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoafflnity labeling.Eur J Pharmacol 1994; 268:9–18.
Bern WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, et al. Overexpression of preceptors in nonneural human tumors.Cancer Res 1991; 51:6558–6562.
Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.Cancer Res 1995; 55:408–413.
Brent PJ, Pang GT. σ binding site ligands inhibit cell proliferation in a mammary and colon carcinoma cell lines and melanoma cells in culture.Eur J Pharmacol 1995; 278:151–160.
Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours.Br J Cancer 2000; 82:1223–1232.
Mach RH, Smith CR, Al Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer.Cancer Res 1997; 57:156–161.
Zamora PO, Moody TW, John CS. Increased binding to sigma sites of N-[l′(2-piperidinyl)ethyl]-4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation.Life Sci 1998; 63:1611–1618.
Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.Cancer Res 2002; 62:313–322.
Crawford KW, Coop A, Bowen WD. σ2 Receptors regulate changes in sphingolipid levels in breast tumor cells.Eur J Pharmacol 2002; 443:207–209.
Wilson AA, Dannals RF, Ravert HT, Sonders MS, Weber E, Wagner HN Jr. Radiosynthesis of sigma receptor ligands for positron emission tomography:11C- and18F-labeled guanidines.J Med Chem 1991; 34:1867–1870.
Musachio JL, Scheffel U, Stathis M, Ravert HT, Mathews WB, Dannals RF. (+)-[C-l l]-cis-N-benzyl-nonnetazocine: a selective ligand for sigma receptorsin vivo. Life Sci 1994; 55:PL225–232.
Dence CS, John CS, Bowen WD, Welch MJ. Synthesis and evaluation of [18F] labeled benzamides: High affinity sigma receptor ligands for PET imaging.Nucl Med Biol 1997; 24:333–340.
Shiue CY, Shiue GG, Zhang SX, Wilder S, Greenberg JH, Benard F, et al. N-(N-Benzylpiperidin-4-yl)-2-[l8F]fluorobenzamide: a potential ligand for PET imaging of sigma receptors.Nucl Med Biol 1997; 24:671–676.
Waterhouse RN, Collier TL.In vivo evaluation of [l8F]l-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET.Nucl Med Biol 1997; 24:127–134.
Ishiwata K, Noguchi J, Ishii S, Hatano K, Ito K, Nabeshima T, et al. Synthesis of [11C]NE-100 labeled in two different positions as a PET a receptor ligand.Nucl Med Biol 1998; 25:195–202.
Kawamura K, Ishiwata K, Tajima H, Ishii S, Shimada Y, Matsuno K, et al. Synthesis andin vivo evaluation of [11C]SA6298 as a PET sigma1 receptor ligand.Nucl Med Biol 1999; 26:915–922.
Mach RH, Huang Y, Buchheimer N, Kuhner R, Wu L, Morton TE, et al. [18F]N-(4′-fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [18F]FDG, and [125I]IUDR.Nucl Med Biol 2001; 28:451–458.
Barbieri F, Sparatore A, Alama A, Novelli F, Bruzzo C, Sparatore F. Novel sigma binding site ligands as inhibitors of cell proliferation in breast cancer.Oncol Res 2003; 13:455–461.
Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H. SR31747A: a peripheral sigma ligand with potent antitumor activities.Anticancer Drugs 2004; 15:113–118.
Kawamura K, Elsinga PH, Kobayashi T, Ishii S, Wang WF, Matsuno K, et al. Synthesis and evaluation of11C- and18F-labeled 1 -[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies.Nucl Med Biol 2003; 30:273–284.
Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, et al.In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors.Nucl Med Biol 2000; 27:255–261.
Kawamura K, Ishiwata K, Shimada Y, Kimura Y, Kobayashi T, Matsuno K, et al. Preclinical evaluation of [11C]SA4503: radiation dosimetry,in vivo selectivity and PET imaging of sigma1 receptors in the cat brain.Ann Nucl Med 2000; 14:285–292.
Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigma receptors in the aged monkey brain.Neurobiol Aging 2003; 24:745–752.
Ishiwata K, Tsukada H, Kawamura K, Kimura Y, Nishiyama S, Kobayashi T, et al. Mapping of CNS sigma1 receptors in the conscious monkey: Preliminary PET study with [11C]SA4503.Synapse 2001; 40:235–237.
Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective σ1 receptor agonist.Eur J Pharmacol 1996; 306:271–279.
Fujimura K, Matsumoto J, Niwa M, Kobayashi T, Kawashima Y, In Y, et al. Synthesis, structure and quantitative structure-activity relationships of σreceptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)pipera-zines.Bioorg Med Chem 1997; 5:1675–1683.
Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of sigma1 receptors in Parkinson’s disease.Acta Neurol Scand 2005; 112:103–107.
Elsinga PH, Kawamura K, Kobayashi T, Tsukada H, Senda M, Vaalburg W, et al. Synthesis and evaluation of [18F]fiuoroethyl SA4503 as a PET ligand for the sigma receptor.Synapse 2002; 43:259–267.
Elsinga PH, Tsukada H, Harada N, Kakiuchi T, Kawamura K, Vaalburg W, et al. Evaluation of [18F]fluorinated sigma receptor ligands in the conscious monkey brain.Synapse 2004; 52:29–37.
van Waarde A, Buursma AR, Hospers GAP, Kawamura K, Kobayashi T, Ishii K, et al. Tumor imaging with two sigma receptor ligands, [18F]FE-SA5845 and [11C]SA4503: a feasibility study.J Nucl Med 2004; 45:1939–1945.
Kubota K, Ishiwata K, Kubota R, Yamada S, Takahashi J, Abe Y, et al. Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-l-methionine.J Nucl Med 1996; 37:320–325.
Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (‘Iressa’, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/ extra cellular signal-regulated kinase 1/2 and EGF receptor/ Akt pathway for proliferation.Mol Cancer Ther 2004; 3:465–472.
Ishiwata K, Kawamura K, Wang WF, Furumoto S, Kubota K, Pascali C, et al. Evaluation of O-[11C]methyl-l-tyrosine and O-[18F]fiuoromethyl-l-tyrosine as tumor imaging tracers by PET.NuclMedBiol 2004; 31:191–198.
Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small cell lung cancer cells.Life Sci 2000; 66:1979–1986.
Leitner ML, Hohmann AG, Patrick SL, Walker JM. Regional variation in the ratio of sigma1 to sigma2 binding in rat brain.Eur J Pharmacol 1994; 259:65–69.
Waterhouse RN, Collier TL.In vivo evaluation of [18F]l-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET.Nucl Med Biol 1997; 24:127–134.
Georg A, Friedl A. Characterization of specific binding sites for [3H]-l,3-di-o-tolyl-guanidine (DTG) in the rat glioma cell line C6-BU-1.Glia 1992; 6:258–263.
Shiue C, Shiue GG, Benard F, Visonneau S, Santoli D, Alavi AA. N-(N-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer.Nucl Med Biol 2000; 27:763–767.
John CS, Vilner BJ, Schwartz AM, Bowen WD. Characterization of sigma receptor binding sites in human biopsied solid breast tumors.J Nucl Med 1996; 37 (Suppl): 267P (abstract).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishiwata, K., Kawamura, K., Kubota, K. et al. Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med 19, 701–709 (2005). https://doi.org/10.1007/BF02985120
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985120